VISEN PHARMA-B (02561) saw its shares jump more than 9% during the trading session. As of the time of writing, the stock was up 7.13%, trading at HK$37.24. According to the Insight database, the company's core product, Lonapegsomatropin, exited the supplementary data request stage on January 12, 2026, indicating that regulatory approval is anticipated imminently. Public information shows that Lonapegsomatropin is a long-acting growth hormone prodrug introduced by VISEN PHARMA-B from Ascendis Pharma. It is developed based on the TransCon temporary linkage technology for the treatment of pediatric growth hormone deficiency (GHD), administered via once-weekly subcutaneous injection, and releases unmodified natural human growth hormone, having already received approval in Europe and the United States. The domestic growth hormone market is currently dominated by daily formulations. The introduction of a weekly formulation is expected to significantly enhance patient compliance, potentially reshape the competitive landscape upon market entry, and address a substantial unmet clinical need.